197 related articles for article (PubMed ID: 29222312)
1. Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond.
Ansell SM
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):618-621. PubMed ID: 29222312
[TBL] [Abstract][Full Text] [Related]
2. T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.
Yang ZZ; Liang AB; Ansell SM
Leuk Lymphoma; 2015; 56(9):2498-504. PubMed ID: 25651421
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
4. The Highs and Lows of Immune-Checkpoint Blockade in Lymphoma.
Ansell SM
Cancer Immunol Res; 2019 May; 7(5):696-700. PubMed ID: 31043393
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma.
Bennani-Baiti N; Thanarajasingam G; Ansell S
Expert Rev Clin Immunol; 2016 Jun; 12(6):673-9. PubMed ID: 26818843
[TBL] [Abstract][Full Text] [Related]
7. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
8. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
Ansell SM
J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
[TBL] [Abstract][Full Text] [Related]
9. The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors.
Menter T; Tzankov A; Dirnhofer S
Hematol Oncol; 2021 Feb; 39(1):3-10. PubMed ID: 33105031
[TBL] [Abstract][Full Text] [Related]
10. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
13. Immune-Checkpoint Inhibitors in B-Cell Lymphoma.
Armengol M; Santos JC; Fernández-Serrano M; Profitós-Pelejà N; Ribeiro ML; Roué G
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430146
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Drugs for the Treatment of B Cell Malignancies.
Ioannou N; Jain K; Ramsay AG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445275
[TBL] [Abstract][Full Text] [Related]
15. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibition in myeloma.
Benson DM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):528-533. PubMed ID: 27913525
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
18. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
Joshi M; Ansell SM
J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
[TBL] [Abstract][Full Text] [Related]
19. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab in the Treatment of Hodgkin Lymphoma.
Ansell SM
Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
